

NEWSLETTER July – August 2019

CEO's greetings

We were honored to be invited to the Neurotrophic factors and Parkinson's meeting organized by [The Cure Parkinson's Trust](#) and [The Michael J. Fox Foundation](#), bringing leading experts in Grand Rapids, MI, USA. A breakthrough in Parkinson's requires broad expertise! It was extremely valuable to discuss e.g. the regulatory landscape and clinical study design with key opinion leaders.

Back in April, Dr. Pauliina Hartiala (Turku University Hospital) presented our Lymfactin® clinical study at the international [EURAPS meeting](#). We were now proud to hear that she was awarded EURAPS' best presentation and invited to hold the same presentation to the American Association of Plastic Surgery. Congrats Pauliina!

Herantis' [Interim Report](#) was published for 1H/19, summarizing our solid progress in the past six months.

CLINICAL STUDIES

- **Breast Cancer Associated Lymphedema:** Phase 2 study AdeLE study is actively recruiting patients in Sweden and Finland. See [Lymfactin web site](#) for more information.
- **Parkinson's disease:** Phase 1–2 study with CDNF fully recruited and active treatment period ongoing.
- **Breast Cancer Associated Lymphedema:** Phase 1 study in long-term follow-up, not actively recruiting patients.

PLANNED ACTIVITIES

- **Aktiespararna**, 10 Sep 2019 in Stockholm: Company presentation to Swedish investors
- **Nordic Life Sciences Days**, 11-12 Sep 2019 in Malmö, Sweden
- **Aktiespararna**, 17 Sep 2019 in Lund: Company presentation to Swedish investors
- **Life Science Investor Meetings**, 18 Sep 2019 in Copenhagen: Company presentation to investors
- **Sijoittaja 2019**, 19 Sep 2019 in Helsinki: Company presentation to investors
- **MDS Congress**, 22-26 Sep 2019 in Nice, France: International Congress of Parkinson's Disease & Movement Disorders
- **Aktiespararna**, 23 Sep 2019 in Göteborg: Company presentation to Swedish investors

Herantis of the month



We're all in the same boat!
Herantis' summer event: sailing in Helsinki

Keep up-to-date on Herantis:



Contact us



@Herantis Pharma



Subscribe

Highlights from our team

Very happy to introduce two new colleagues: Dr. Natalia Kuleshkaya, Senior Scientist, brings important pharmacology expertise in our CDNF and xCDNF development; and Rebecka Holmnäs, our trainee for the past two years, joins Herantis full-time as Project Manager after completing her master's thesis. Welcome!

Topics of interest

Artificial Intelligence (AI) is currently a very hot topic. Some believe it will solve all the problems of mankind (while others believe just the opposite). We have also been asked whether AI could revolutionize drug development. Not any time soon; not in our field, aiming at true breakthroughs. Why not? [Read our recent blogging.](#)

Herantis web site being updated

Herantis has evolved significantly in the past five years. We have decided to update our web site to help all stakeholders - patients, investors, partners, and anyone else interested - find the information they are looking for. Stay tuned at [Herantis.com!](#)